Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: YM178 Clear all
Active, not recruiting Phase 4 Interventional

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

NCT05604222
View directory record Official record
Conditions
Urgency Urinary Incontinence, Nocturia
Interventions
Mirabegron 50 MG, Brief Behavioral Treatment for Insomnia
Drug · Behavioral
Lead sponsor
Shachi Tyagi
Other
Eligibility
60 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 4 Interventional Results available

Mirabegron in Parkinson Disease and Impaired Cognition

NCT02536976
View directory record Official record
Conditions
Parkinson Disease, Overactive Bladder, Impaired Cognition
Interventions
mirabegron, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Golden Valley, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MIrabegron and Physiological Function in Cold Environments

NCT05990387
View directory record Official record
Conditions
Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Incontinence Without Memory Problems

NCT02436889
View directory record Official record
Conditions
Urge Incontinence, Urinary Incontinence, Urge
Interventions
Mirabegron, Tolterodine Tartrate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 20, 2026, 7:57 PM EDT
Withdrawn Phase 4 Interventional

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

NCT02981459
View directory record Official record
Conditions
Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions
Mirabegron
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Mirabegron For Erectile Dysfunction

NCT02916693
View directory record Official record
Conditions
Erectile Dysfunction, Overactive Bladder, Urinary Incontinence
Interventions
Mirabegron
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Early Phase 1 Interventional

Brown Fat Activation Study

NCT02919176
View directory record Official record
Conditions
Obese, Metabolic Syndrome
Interventions
Mirabegron, Pioglitazone, Mirabegron and Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

ADRB3 Signaling Pathway in Human Adipose Tissue

NCT05634174
View directory record Official record
Conditions
Obesity, Prediabetes
Interventions
Mirabegron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

NCT00776516
View directory record Official record
Conditions
Pharmacokinetics of YM178
Interventions
mirabegron, rifampin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Mirabegron and Physiological Function in Cold Environments

NCT04766021
View directory record Official record
Conditions
Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931
View directory record Official record
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Early Phase 1 Interventional

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

NCT05880862
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
Interventions
Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride
Behavioral · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 99 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 1 Interventional

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

NCT03049462
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Mirabegron, B Complex Plus Vitamin C Tablets
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

NCT02092181
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Daniel Burdick, MD
Individual
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 3 Interventional Results available

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 20, 2026, 7:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH

NCT07829029
View directory record Official record
Conditions
Nocturia, Nocturnal Urinary Incontinence
Interventions
TolterodineTartrate ER, Mirabegron, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

NCT01199523
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo, mirabegron, moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 20, 2026, 7:57 PM EDT
Terminated Early Phase 1 Interventional

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

NCT03411252
View directory record Official record
Conditions
Achalasia
Interventions
Mirabegron 50 MG, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 20, 2026, 7:57 PM EDT
Completed Phase 2 Interventional Results available

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

NCT02744430
View directory record Official record
Conditions
Ureteral Obstruction, Flank Pain
Interventions
Mirabegron, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 20, 2026, 7:57 PM EDT
Not yet recruiting Phase 4 Interventional

Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease

NCT07627529
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Overactive bladder antimuscarinic deprescribing
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 20, 2026, 7:57 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanisms for Activation of Beige Adipose Tissue in Humans

NCT04666636
View directory record Official record
Conditions
PreDiabetes
Interventions
Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 20, 2026, 7:57 PM EDT